VRTX Tshuag: Kev taw qhia Upbeat Tom qab lub quarterly profit yeej, muag hauv kab

Vertex Cov Kev Tshuaj (VRTX) muab qhov kev pom zoo rau hnub Tuesday rau nws cov khob cij-thiab-butter cystic fibrosis cov tshuaj, tab sis VRTX Tshuag poob ntawm kev muag khoom uas nyuam qhuav ua tau raws li kev kwv yees.

X

Thaum lub Kaum Ob Hlis Lub Kaum Ob Hlis, hloov Vertex cov nyiaj tau los tau nce 25% rau $ 3.76 ib feem, siab dua Txoj Kev kwv yees rau $ 3.53. Kev muag khoom tuaj ntawm $ 2.3 nphom piv rau kev cia siab rau $ 2.31 nphom, raws li FactSet.

Hauv kev teb, VRTX cov khoom lag luam poob 0.5% mus rau ze 307 hauv kev ua haujlwm tom qab teev. Thaum tsis tu ncua trading ntawm lub Tshuag lag luam hnub no, shares inched 1.2% siab dua thiab kaw ntawm 308.54.

VRTX Tshuag: Trikafta Tsav Kev Loj Hlob

Tsis xav txog, qhov kev loj hlob zoo tshaj plaws nyob rau lub quarter yog los ntawm Vertex's triple regimen rau cystic fibrosis, Trikafta. Cov nyiaj tau los ntawm cov tshuaj ntawd tau nce ntau dua 19% rau $ 2.02 billion. Qhov ntawd tsuas yog ua ntej ntawm cov kws tshuaj ntsuam hu rau $ 1.97 billion.

Lub caij no, kev muag khoom ntawm Vertex's lwm txoj kev kho mob cystic fibrosis poob. Lub tuam txhab lees paub qhov no rau cov neeg mob qhov kev txiav txim siab hloov mus rau Trikafta los ntawm cov tshuaj laus. Trikafta tuaj yeem kho 90% ntawm cov neeg mob uas mob ntsws.

Vertex kuj lees paub tus khub Tshuaj Ntsuab Los Kho Ntau Yam (Crsp) tab tom ua kom tiav kev xa nws daim ntawv thov rau kev hloov kho noob rau cov kab mob ntawm tes thiab beta thalassemia thaum kawg lub Peb Hlis. Yog tias Lub Chaw Tswj Xyuas Khoom Noj thiab Tshuaj pom zoo, cov tshuaj yuav yog thawj zaug siv CRISPR noob kho kom raug ntaus lub khw.

Cov kws tshuaj ntsuam tom qab VRTX cov khoom lag luam kuj tseem saib xyuas lub tuam txhab kev siv zog hauv kev mob, ntshav qab zib thiab kab mob ntawm daim siab thiab ob lub raum.

"Peb qhov kev vam meej hauv 2022 tau tsim lub hauv paus rau kev kho ntau tus neeg mob cystic fibrosis, pib ntau yam kev kho mob tshiab nyob rau lub sijhawm ze, ua tiav cov kev kho mob tseem ceeb thiab ua kom muaj kev loj hlob ntxiv rau ntau xyoo tom ntej," Tus Thawj Coj Reshma Kewalramani tau hais hauv nqe lus sau. .

Kev Taw Qhia Upbeat Ntawm CF Tshuaj

Rau lub xyoo, Vertex coj mus rau $ 9.55 billion rau $ 9.7 billion hauv kev muag khoom ntawm nws cov kev kho mob cystic fibrosis. Qhov nruab nrab ntawm lub tuam txhab kev taw qhia yog siab dua VRTX cov kws tshuaj ntsuam xyuas cov khoom hu rau $ 9.55 billion hauv cov khoom muag.

Cov kev taw qhia suav nrog kev cia siab tias Trikafta yuav tau txais kev pom zoo los ntawm FDA hauv cov menyuam yaus hnub nyoog 2-5 xyoos.

"Peb cia siab tias muaj xim ntau dua ntawm kev hu xov tooj rau qib uas qhov no sawv cev txuas ntxiv (cystic fibrosis) cov neeg mob kev loj hlob raws li lub tuam txhab ua kom tau txais txiaj ntsig txuas ntxiv ntawm cov neeg mob hluas thiab khaws cov nyiaj rov qab thoob ntiaj teb ntxiv rau qhov muaj peev xwm pab tau los ntawm qhov pib bolus ntawm (sickle cell lossis beta thalassemia) cov neeg mob, "RBC Capital Markets kws tshuaj ntsuam Brian Abrahams tau hais hauv tsab ntawv ceeb toom.

Nws muaj ib qho kev ntsuam xyuas thiab 303 tus nqi hom phiaj ntawm VRTX Tshuag.

Ua raws li Allison Gatlin ntawm Twitter ntawm @IBD_AGatlin.

KOJ UA LI CAS:

Top-notch Medical Stocks Incyte, Haemonetics Beat - Thiab Shares Crumbled

Catalent hits plaub-hli siab raws li Danaher tshaj tawm tias Mulls A Takeover

Nrhiav Cov Khoom Noj Zoo Tshaj Niaj Hnub No Kom Tau Saib Nrog IBD 50

Pom Cov Txiaj Ntsig Zoo Li Qub Nrog MarketSmith Txawv Cov Qauv Cim & Cov Duab Ntsej Muag

Cov Khoom Cuam Tshuam Yuav Yooj Yim Thiab Saib Xyuas: IPOs Sab saum toj, Lub Kaus Loj Loj Thiab Cov Me Me, Cov Lus Qhia Loj Hlob